Diagnostic  Reagents

Provision of reagents for clinical

  • Okayama Plant

Early diagnosis and treatment through highly accurate testing

  • Contributing to early detection and treatment of various diseases through highly accurate testing.
  • Contributing to early detection and treatment of various diseases through highly accurate testing.

The mission of Alfresa Pharma is "to deliver previously unseen, new in vitro diagnostic reagents," and we are now developing, producing and marketing diagnostic devices that will be used in medical examinations and hospital laboratories.For example, we have developed unique technologies in colloidal gold reagents, which use a solution of ultrafine particles of gold. In particular, we have succeeded in the simultaneous quantitative assays of hemoglobin and transferrin for the first time in the world. This fecal immunochemical test (FIT) is used for colorectal cancer screening and has been contributing to early detection and rapid diagnosis of the disease. We have developed a FIT analyzer to measure concentrations of urine analytes, in addition to fecal analytes.

POCT* products supporting simple, fast, and highly precise diagnoses

  • POCT* products supporting simple, fast, and highly precise diagnoses

We are developing and selling POCT products that support on the spot, simple, and fast diagnosis for outpatients, at bedside,GP 's offices, and emergency services. They are useful as an explanation of the diagnosis, treatment, and prognosis of influenza or adenovirus infection and other infectious diseases.

*POCT (Point-Of-Care Testing): A rapid test to be performed at the patient's side in medical and nursing fields.

Home

Company Information

Business Domain

  • Business Domain Index
  • Overseas Sales
  • API Sales
  • Pharmaceuticals
  • Diagnostic Regents
  • Medical Devices & Equipment
  • Contract Manufacturing
  • Contract Manufacturing
  • alfresa Alfresa Holdings Corporation
  • alfresa group